What FendX Technologies does

FendX Technologies Inc. (CSE: FNDX; OTCQB: FDXTF; FSE: E8D0) is a Canadian pre-revenue nanotechnology company developing surface protection products designed to reduce the spread of pathogens on high-touch surfaces and medical devices. The company's portfolio centers on three core technologies: (1) an antimicrobial nanoparticle-based liquid surface coating applied via brush or roller, which has demonstrated 99% reduction in MRSA and P. aeruginosa in lab testing; (2) a lubricated Foley catheter coating developed under a Collaborative Research Agreement with McMaster University, with demonstrated 99% reduction of E. coli in initial testing; and (3) an AI-enabled mobile application that uses smartphone imaging combined with reagents for real-time microbial contamination detection on surfaces (US Provisional #63/835,582). The IP base is anchored by exclusive McMaster University nanotechnology licenses, three pending US provisional applications, one granted US patent (12,390,545 B2, open-cell foam), and a pending US/EU patent family for foam-based wound treatment.

FendX is led by President & CEO Dr. Carolyn Myers (MBA, PhD), whose prior leadership roles include Allergan PLC, Mylan Technologies, Dey Laboratories, and Pharmacia, with CFO Rose Zanic (CPA, CA) providing capital markets and Canadian public-company administration experience. The company employs 1-10 people, has its registered office in Vancouver, BC, and operates as a publicly traded entity on the Canadian Securities Exchange (with cross-listings on OTCQB and Frankfurt).

The business model is pre-commercial: the company is not yet generating revenue and is pursuing commercialization through partnership and licensing pathways. Distribution is intended to be OEM/embedded (coatings licensed to or embedded in third-party products) and enterprise-focused across two customer segments. The primary segment is healthcare settings, including hospitals, healthcare facilities, and Foley catheter applications where the goal is to reduce healthcare-associated infections. The secondary segment is consumer and commercial markets, including transportation (airplanes, trains, buses), entertainment venues (arenas, theaters, casinos), hospitality, schools, and office buildings. The GTM motion is enterprise field sales, with commercialization advancing through an FDA regulatory pathway assessment (Innovotech Labs, April 2026) and pilot-scale manufacturing (Galenvs Sciences, April 2026). The company recently executed a strategic pruning, terminating the REPELWRAP film program (March 2026) and the Aquaox LLC collaboration (April 2026) to focus resources on the liquid coating, catheter coating, and AI detection app.

Name

FendX Technologies

Legal name

FendX Technologies Inc.

Website

https://fendxtech.com/

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

FendX Technologies is a Canadian pre-revenue nanotechnology company developing antimicrobial liquid surface coatings, a Foley catheter coating, and an AI-enabled mobile pathogen-detection app to reduce pathogen spread on high-touch surfaces for healthcare and consumer/commercial markets.

Ownership category

akta.pro rank

Product category

Antimicrobial Surface Protection

NAICS

Research and Development in Nanotechnology (541713), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Specialty Cleaning, Polishing And Sanitation Preparations (2842)

akta.pro primary industry

Natural/Plant-Based Surface Disinfectants (CRAJANAI)

Keywords

• Antimicrobial surface coatings
• Nanotechnology surface protection
• Medical device coatings
• AI pathogen detection
• Infection control products

Headquarters

HQ city

Oakville

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Product Sales (Future): The company is pre-revenue and has not yet commercialized products. Revenue is expected from sale of surface coatings, Foley catheter coatings, and AI-powered detection applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

FendX Technologies develops and intends to commercialize nanotechnology-based surface protection products that reduce the spread of pathogens on high-touch surfaces and medical devices. Its core offerings are an antimicrobial liquid surface coating, a lubricated Foley catheter coating, and an AI-powered mobile app for real-time microbial contamination detection. Products are pre-commercial and in development, with pilot-scale manufacturing underway.

Product overview

FendX Technologies is developing a portfolio of surface protection products to reduce the spread of pathogens. The product portfolio consists of three main offerings: (1) the Antimicrobial Liquid Surface Coating, a scalable nanoparticle-based coating applied via brush/roller for long-lasting antimicrobial protection on high-touch surfaces; (2) the Foley Catheter Coating, a specialized lubricated coating for medical catheters designed to inhibit bacterial growth; and (3) the AI-Driven Surface Contamination Detection App, a mobile application using AI and smartphone imaging to detect pathogens on surfaces in real-time. These products are designed to complement each other as integrated solutions—a layered protection approach combining physical coatings with digital monitoring capabilities. The company previously developed REPELWRAP film technology but discontinued it in March 2026 to focus on the liquid coating.

Differentiator

Problem solved

Functional benefit

Brands

• REPELWRAP: Film coating technology for surface protection (discontinued development as of March 2026)
• Antimicrobial Liquid Surface Coating
• Foley Catheter Coating
• AI-Powered Pathogen Detection App

Products and services

• Antimicrobial Liquid Surface Coating A scalable nanoparticle-based liquid coating designed for easy application on high-touch surfaces via brush or roller, providing durable, long-lasting antimicrobial protection with demonstrated 99% reduction in MRSA and P. aeruginosa. Targeted at hospitals, transportation, hospitality, education, entertainment, and other high-touch environments.
• Foley Catheter Coating A specialized lubricated antimicrobial coating for Foley catheters designed to inhibit bacterial growth, demonstrating 99% reduction of E. coli in initial testing with strong durability characteristics. Developed under collaboration with McMaster University and intended for medical device manufacturers and healthcare providers.
• AI-Driven Surface Contamination Detection App An AI-enabled mobile application designed to detect microbial contamination on surfaces in real-time using smartphone imaging and reagents. Complements FendX's physical coating technologies by enabling real-time monitoring and data-driven hygiene solutions for facility managers and infection-prevention teams.

Quantifiable outcome

• 99% reduction in MRSA and P. aeruginosa with liquid surface coating
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Five partnerships are on record, tiered major, core and minor.

• Innovotech Labs CorporationmajorImplementation/ SI/ Consulting Partner · 28 April 2026Engaged to conduct regulatory research to determine the appropriate FDA classification and regulatory pathway for FendX's coated Foley catheter product. The scope includes assessment of regulatory requirements outlining the recommended FDA regulatory pathway. Following pathway determination, the company may engage Innovotech for antimicrobial testing services to support further development efforts.
• Galenvs Sciences Inc.coreTechnology or Integration · 14 April 2026Canadian contract manufacturing organization engaged to initiate pilot-scale manufacturing of FendX's liquid surface coating. The statement of work focuses on establishing scalable manufacturing processes with production of three independent lots to evaluate consistency and antimicrobial performance. This represents a key step toward commercialization of the surface coating technology.
• McMaster UniversitycoreStrategic or Co-development Partner · 27 March 2026Ongoing collaboration under a Collaborative Research Agreement (CRA) for Foley catheter coating development. The company also has exclusive licenses for nanotechnology IP from McMaster. An amendment was signed on March 27, 2026 (effective November 30, 2025) to extend the catheter CRA term to May 31, 2026 and reduce payment commitments. The company terminated license agreements related to REPELWRAP film and original liquid coating formulation while maintaining excellent collaborative relations for future initiatives.
• Aquaox LLCminorStrategic or Co-development Partner · 17 November 2025MOU signed November 17, 2025 to develop advanced formulations of eco-friendly pathogen-eliminating agents using Aquaox's hypochlorous acid (HOCl) technologies. A collaboration agreement was entered January 20, 2026 to assess technical feasibility. However, both the Collaboration Agreement (dated January 20, 2026) and MOU (dated November 17, 2025) were terminated in April 2026 as the initial technical feasibility phase was deemed not feasible. The company has since shifted focus to its existing surface protection solutions.
• Outside The Box Capital Inc.minorGTM or Marketing Partner · 11 March 2025Provides investor relations, marketing and distribution services including social media (Reddit, Discord, Telegram, X/Twitter, StockTwits), digital and influencer-based marketing, content creation and distribution. The agreement was renewed and extended to June 30, 2026 with a fee reduction of $28,080 (inclusive of taxes). The company and OTB are arm's length.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/fendxtech
• LinkedInlinkedin.com/company/fendx-technologies
• Xx.com/fendxtech

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FendX Technologies